Study compares cancer drug cost, benefit

June 6, 2017 by Anne Craig
Credit: CC0 Public Domain

Queen's University researcher Christopher Booth reveals the price of new cancer therapies is not associated with treatment effectiveness.

A new study from Queen's University professor Christopher Booth has revealed the pricing of appears to have no relationship to their effectiveness.

Through the review it was revealed that the most expensive drugs were not the most beneficial.

"Most members of the public (and many patients) may not understand that when they read about a new 'breakthrough cancer therapy' in the media it usually does not cure cancer but extends survival by a few weeks or perhaps a few months," says Dr. Booth (Oncology). "Given that these drugs are very expensive and have important side effects, these small improvements may not lead to real improvements in the overall health and well-being of our patients or society as a whole."

Using frameworks developed by the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO), Dr. Booth and his team studied all randomized controlled trials of new cancer drugs in non-small cell lung cancer, breast cancer, colorectal cancer and pancreatic cancer over a four-year period.

The study found that there was no relationship between the price of a cancer and the extent to which it improves patient survival and quality of life. The authors concluded that to deliver optimal cancer care in a sustainable health system will require oncologists and policy makers to reconcile the disconnect between drug cost and clinical benefit.

"Our data does not suggest the use of these agents is inappropriate. These treatments have been established based on well-conducted clinical trials," explains Dr. Booth. "Our concern is that the very small magnitude of benefit associated with many new treatments may not be fully appreciated by the public and by some patients."

Dr. Booth advocates moving towards a value-based system where treatments and interventions that have a greater benefit for patients and society receive more resources than treatments that offer little benefit. He says one model that is being considered is value-based pricing where cancer drugs that offer the largest benefit are sold at a higher price than drugs with negligible benefit.

"In our current system the price of a new cancer drug has no relationship to its benefit but is largely driven by the maximum price the market will bear," says Dr. Booth. "A value-based pricing system would encourage companies and researchers to focus on developing more effective medicines by offering greater financial returns for those therapies with substantial benefit and smaller financial returns for treatments with negligible benefits. If you think about it, this relationship between quality and cost is what drives most economic transactions and it has always seemed strange to me that it does not apply to new medicines.

The study was published in The Lancet Oncology.

Explore further: New drugs, higher costs offer little survival benefit in advanced lung cancer

More information: Joseph C Del Paggio et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks, The Lancet Oncology (2017). DOI: 10.1016/S1470-2045(17)30415-1

Related Stories

New drugs, higher costs offer little survival benefit in advanced lung cancer

January 5, 2017
According to a University of Colorado Cancer Center study published this week in the Journal of Clinical Oncology, a decade that saw the development of new therapies for non-small cell lung cancer resulted in little survival ...

England's Cancer Drugs Fund 'failed to deliver meaningful value to patients and society'

April 27, 2017
Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may have resulted in patients suffering unnecessarily ...

Researchers develop framework for value-based pricing of cancer drugs

August 27, 2015
At a time when cancer drug prices are rising rapidly, an innovative new study provides the framework for establishing value-based pricing for all new oncology drugs entering the marketplace. Using a highly sophisticated economic ...

What price for a year of life? Cancer specialists offer contradictory advice

April 20, 2012
Cancer doctors prescribe medicines with little consideration of the cost, meaning they don't demand any more benefit (in months of survival) from a very expensive drug than from a less expensive one, a new research report ...

Drug combination shows benefit in RAS-driven cancers

April 3, 2017
Cancers driven by the RAS oncogene are aggressive and difficult to treat, and thus far precision drugs haven't been able to target the mutant RAS gene successfully.

Expensive new cancer drugs have little effect on survival of many cancers

November 9, 2016
Despite considerable investment and innovation, new cancer drugs approved in the past 10 years may have little effect on survival in adults with cancer, raising a number of concerns, argues an expert in The BMJ today.

Recommended for you

Breast cancer researchers find bacteria imbalance link

October 19, 2017
Researchers in the United States have uncovered differences in the bacterial composition of breast tissue of healthy women versus those with breast cancer.

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

US regulators approve 2nd gene therapy for blood cancer

October 19, 2017
U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.